SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 76 of 94
Word Count: 1437
Character Count: 9790

Document Content:

Form S-1 under the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further information about us and the common stock offered hereby, reference is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete, please see the copy of the contract or document that has been filed for the complete contents of that contract or document. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The exhibits to the registration statement should be reviewed for the complete contents of these contracts and documents.

currently do not file periodic reports with the SEC. Upon the completion of this offering, we will be required to file periodic reports,
proxy statements and other information with the SEC pursuant to the Exchange Act. The SEC maintains a website that contains reports,
proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the
website is www.sec.gov.

also maintain a website at www.bioventrix.com. Upon completion of this offering, you may access these materials at our website
free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained
in, or that can be accessed through, our website is not a part of, and is not incorporated into, this prospectus.

BIOVENTRIX,
INC.

CONSOLIDATED
FINANCIAL STATEMENTS

Three
Months Ended

March
31, 2026 and 2025

Table
of Contents

Consolidated Financial Statements
(unaudited):

Consolidated Balance Sheets (unaudited)	F-2

Consolidated Statements of Operations (unaudited)	F-3

Consolidated Statements of Changes in Stockholders’ Deficit (unaudited)	F-4

Consolidated Statements of Cash Flows (unaudited)	F-5

Notes to Consolidated Financial Statements (unaudited)	F-6

BIOVENTRIX,
INC.

Consolidated
Balance Sheets

March 31, December 31,

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents $	924,026 $	1,838,121

Prepaid expenses 158,213 251,734

Total current assets 1,082,239 2,089,855

Long-term assets:

Property and equipment, net 90,390 101,689

Lease right of use asset 201,446 231,785

Deposits 147,586 145,532

Total long-term assets 439,422 479,006

Total assets $	1,521,661 $	2,568,861

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current liabilities:

Accounts payable $	2,155,516 $	2,088,060

Accrued liabilities 3,791,100 2,779,397

Lease liability, current 147,349 146,323

Convertible notes 10,875,000 9,857,477

Discount on convertible notes (1,277,627	) (1,188,905	)

Total current liabilities 15,691,338 13,682,352

Long-term liabilities:

Derivative liability 1,533,647 1,349,735

Lease liability, non-current 68,998 101,955

Total long-term liabilities 1,602,645 1,451,690

Total liabilities 15,691,338 15,134,042

Stockholders’ deficit:

Common stock, $0.0001 par value, 25,000,000 shares authorized; 5,723,895 and 5,712,645 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 572 571

Convertible preferred stock, $0.0001 par value, 12,500,000 shares authorized; 1,302,950 and 1,565,000 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 131 157

Additional paid-in capital 218,725,118 218,675,435

Accumulated deficit (234,498,143	) (231,241,344	)

Total stockholders’ deficit (15,772,322	) (12,565,181	)

Total liabilities and stockholders’ deficit $	1,521,661 $	2,568,861

See
accompanying notes which are an integral part of these financial statements.

BIOVENTRIX,
INC.

Consolidated
Statements of Operations

(unaudited)

For the Three Months Ended March 31,

Operating income:

Sales $	- $	-

Cost of goods sold - -

Gross profit - -

Operating expenses:

Research and development 597,576 108,390

Selling, general and administrative 2,088,345 967,478

Total operating expenses 2,685,921 1,075,868

Loss from operations (2,685,921	) (1,075,868	)

Other expense (income):

Interest, net 590,669 190,124

Other (19,791	) 161

Total other expense (income) 570,878 190,285

Loss from operations before provision for income taxes (3,256,799	) (1,266,153	)

Provision for Income taxes - -

Net loss $	(3,256,799	) $	(1,266,153	)

Net loss per share – basic and diluted $	(0.57	) $	(0.22	)

Weighted average common shares outstanding – basic and diluted 5,723,895 5,636,283

See
accompanying notes which are an integral part of these financial statements.

BIOVENTRIX,
INC.

Consolidated
Statements of Changes in Stockholders’ Deficit

(unaudited)

Preferred Stock Common Stock Additional Paid Accumulated Total Stockholders’

Shares Amount Shares Amount In Capital Deficit Deficit

Balances, January 1, 2025 1,565,000 $	157 5,616,390 $	561 $	218,533,820 $	(223,573,673	) $	(5,039,135	)

Stock-based compensation expense 57,753 $	6 $	46,197 $	46,203

Net loss $	(1,266,153	) $	(1,26,153	)

Balances, March 31, 2025 1,565,000 $	157 5,674,143 $	567 $	218,580,017 $	(224,839,826	) $	(6,259,085	)

Balances, January 1, 2026 1,565,000 $	157 5,712,645 $	571 $	218,675,435 $	(231,241,344	) $	(12,565,181	)

Retirement of preferred stock contributed by shareholder (262,050	) $	(26	) $	26 $	- $	-

Stock-based compensation expense 11,250 $	1 $	49,657 $	49,658

Net loss $ $	(3,256,799	) $	(3,256,799	)

Balances, March 31, 2026 1,302,950 $	131 5,723,895 $	572 $	218,725,118 $	(234,498,143	) $	(15,772,322	)

See accompanying notes which are an integral part of these financial statements.

BIOVENTRIX,
INC.

Consolidated
Statements of Cash Flows

(unaudited)

For the Three Months Ended March 31,

Cash flows from operating activities:

Net loss $	(3,256,799	) $	(1,266,153	)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation 11,299 11,299

Stock based compensation 49,658 46,202

Change in fair value of derivative liabilities (12,716	) -

Amortization of discount on convertible notes 165,039 -

Changes in operating assets and liabilities:

Accounts payable 67,456 193,433

Accrued liabilities 1,011,703 248,900

Lease liability (31,931	) (27,599	)

Lease asset 30,339 27,116

Deposits (2,054	) (100,000	)

Prepaid expense 93,521 (59,443	)

Net cash used in operating activities (1,874,485	) (926,245	)

Cash flows from investing activities:

Purchases of property and equipment - -

Net cash used in investing activities - -

Cash flows from financing activities:

Proceeds from convertible notes payable 960,390 450,000

Net cash provided by financing activities 960,390 450,000

Decrease in cash and cash equivalents $	(914,095	) $	(476,245	)

Cash and cash equivalents, start of period 1,838,121 2,637,635

Cash and cash equivalents, end of period $	924,026 $	2,161,390

Supplemental disclosure of cash flow information

Non-cash operating activities:

Derivative liability $	196,628 $	-

Non-cash financing activities:

Discount on convertible note $	57,133 $	-

Retirement of preferred stock contributed by shareholder $	26 $	-

Cash paid during the period for income taxes $	- $	-

See accompanying notes which are an integral part of these financial statements.

BIOVENTRIX, INC.

Notes
to Consolidated Financial Statements

March 31, 2026 and 2025

(unaudited)

Note
1 – Organization and operations and basis of presentation

BioVentrix,
Inc. (the “Company”) is a private medical device company that was incorporated in the state of California on October 15,
2003, as CHF Technologies, Inc. During 2012, the Company created BioVentrix, Inc., a Delaware corporation, which it then merged into
CHF Technologies, Inc. From 2004 through 2007, the Company marketed products and services to treat various heart related issues. In 2007,
the Company ceased sales and marketing of these product lines and began developing a new product to treat heart failure. In June 2016
the Company received CE Mark Certification for its product Revivent TC™ TransCatheter Ventricular Enhancement System (“Revivent”).
In 2016 the Company tested and marketed the system in Europe. In May 2016 the Company received Food and Drug Administration (“FDA”)
Investigational Device Exemption (“IDE”) approval for its clinical trial and began to test and market the system in the United
States in 2017. The Company’s trial, which was completed in 2023 (the “ALIVE Trial”), achieved statistical significance
with a subpopulation on functional status and Quality-of-Life (“QoL”) measures, three of the measures in our efficacy endpoint
composite. Leveraging this subpopulation finding, the Company proposed and was approved by the FDA via an IDE for the RELIVE Trial for
84 treated patients and 42 control patients, for a total of 126 trial patients (135 randomized patients starting the trial to account
for trial patient attrition). In November 2024, the Company received an IDE from the FDA under Breakthrough Therapy Designation (“BTD”)
to begin the RELIVE Trial. The FDA grants BTD if preliminary clinical evidence suggests the procedure may improve substantially upon
at least one clinically significant endpoint for a serious or life-threatening condition compared to existing therapies. The first RELIVE
trial patient was treated on September 29, 2025.

Going
Concern – The accompanying financial statements are prepared in accordance with generally accepted accounting principles applicable
to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.